Literature DB >> 9267997

The pathogenesis of NIDDM involves a defective expression of the GIP receptor.

J J Holst1, J Gromada, M A Nauck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267997     DOI: 10.1007/s001250050779

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  27 in total

1.  Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.

Authors:  Frédéric Preitner; Mark Ibberson; Isobel Franklin; Christophe Binnert; Mario Pende; Asllan Gjinovci; Tanya Hansotia; Daniel J Drucker; Claes Wollheim; Rémy Burcelin; Bernard Thorens
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 2.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans.

Authors:  Erik Ingelsson; Claudia Langenberg; Marie-France Hivert; Inga Prokopenko; Valeriya Lyssenko; Josée Dupuis; Reedik Mägi; Stephen Sharp; Anne U Jackson; Themistocles L Assimes; Peter Shrader; Joshua W Knowles; Björn Zethelius; Fahim A Abbasi; Richard N Bergman; Antje Bergmann; Christian Berne; Michael Boehnke; Lori L Bonnycastle; Stefan R Bornstein; Thomas A Buchanan; Suzannah J Bumpstead; Yvonne Böttcher; Peter Chines; Francis S Collins; Cyrus C Cooper; Elaine M Dennison; Michael R Erdos; Ele Ferrannini; Caroline S Fox; Jürgen Graessler; Ke Hao; Bo Isomaa; Karen A Jameson; Peter Kovacs; Johanna Kuusisto; Markku Laakso; Claes Ladenvall; Karen L Mohlke; Mario A Morken; Narisu Narisu; David M Nathan; Laura Pascoe; Felicity Payne; John R Petrie; Avan A Sayer; Peter E H Schwarz; Laura J Scott; Heather M Stringham; Michael Stumvoll; Amy J Swift; Ann-Christine Syvänen; Tiinamaija Tuomi; Jaakko Tuomilehto; Anke Tönjes; Timo T Valle; Gordon H Williams; Lars Lind; Inês Barroso; Thomas Quertermous; Mark Walker; Nicholas J Wareham; James B Meigs; Mark I McCarthy; Leif Groop; Richard M Watanabe; Jose C Florez
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

Review 4.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

5.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Authors:  J J Meier; B Gallwitz; M Askenas; K Vollmer; C F Deacon; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 7.  Gut peptides and type 2 diabetes mellitus treatment.

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 4.810

Review 8.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

9.  Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.

Authors:  Luan Shu; Aleksey V Matveyenko; Julie Kerr-Conte; Jae-Hyoung Cho; Christopher H S McIntosh; Kathrin Maedler
Journal:  Hum Mol Genet       Date:  2009-04-21       Impact factor: 6.150

10.  Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

Authors:  Chee W Chia; Olga D Carlson; Wook Kim; Yu-Kyong Shin; Cornelia P Charles; Hee Seung Kim; Denise L Melvin; Josephine M Egan
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.